United Therapeutics stock had its Relative Strength (RS) Rating upgraded from 71 to 89 Tuesday. On a weekly chart, the relative strength line for the biotech stock is sitting at a new high territory, earning it a Blue Dot in MarketSmith.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
This unique rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the last 52 weeks matches up against other publicly traded companies.
Over 100 years of market history reveals that the best-performing stocks typically have an RS Rating north of 80 as they begin their biggest price moves.
Looking For Winning Stocks? Try This Simple Routine
Is United Therapeutics Stock A Buy?
United Therapeutics stock is building a consolidation with a 218.47 buy point. Volume has been ramping up in recent trading days. See if the stock can clear the breakout price in volume at least 40% above average.
The biotech stock's relative strength line has moved into new high ground, a promising sign of market leadership.
Earnings grew 44% last quarter, up from 6% in the prior report. Revenue also increased, from 8% to 22%.
United Therapeutics stock holds the No. 7 rank among its peers in the Medical-Biomed/Biotech industry group. Vertex Pharmaceuticals and Amphastar Pharmaceuticals are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
